ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update Read more about ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update
ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results Read more about ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results
ZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term Cardiovascular Outcomes Read more about ZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term Cardiovascular Outcomes
ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression Read more about ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression
ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its Progression Read more about ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its Progression
ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones Read more about ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones
ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress Read more about ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress
ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds Read more about ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds
ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator™ VAR 200 in a Patient with ApoCII Amyloidosis Read more about ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator™ VAR 200 in a Patient with ApoCII Amyloidosis
ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator™ VAR 200’s Phase 2a Clinical Trial in Patients with Diabetic Kidney Disease (DKD) Read more about ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator™ VAR 200’s Phase 2a Clinical Trial in Patients with Diabetic Kidney Disease (DKD)
